Achieve Life Sciences Welcomes Dr. Mark Rubinstein
In a significant move towards enhancing its leadership, Achieve Life Sciences, Inc. (NASDAQ: ACHV), a trailblazer in developing solutions for smoking cessation and nicotine dependence, has appointed Dr. Mark L. Rubinstein as the new Head of Medical Affairs. Dr. Rubinstein’s impressive two-decade background in clinical medicine and medical affairs aligns perfectly with Achieve’s goals.
Dr. Rubinstein's Expertise and Experience
Bringing forth a wealth of knowledge, Dr. Rubinstein has a robust history focused on preventative medicine and interventions in nicotine cessation. His dual experience across academic institutions and corporate environments makes him an essential addition to the Achieve Life Sciences team. This experience includes noteworthy roles such as the Head of Medical Affairs at Blip and Vice President of Global Scientific Affairs at Juul Labs.
Leadership Insights from Achieve's CEO
Rick Stewart, the CEO of Achieve Life Sciences, expressed excitement over Dr. Rubinstein's appointment, stating, "We are thrilled to welcome Mark to our team at this pivotal time. His vast experience in smoking and vaping cessation will significantly impact our efforts to combat nicotine dependence and enhance public health outcomes." This statement indicates the alignment of Dr. Rubinstein’s expertise with Achieve’s mission.
Dr. Rubinstein’s Vision for Cytisinicline
Upon his appointment, Dr. Rubinstein shared his enthusiasm, stating, "I am honored to join Achieve at such an exciting time as we move closer to anticipated FDA approval and commercialization of cytisinicline." His insight into the potential of cytisinicline, believed to be the first new treatment for nicotine dependence in two decades, highlights the importance of the drug in assisting individuals in their quest to quit nicotine.
Academic and Research Contributions
Dr. Rubinstein has served as Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), for nearly 20 years. His extensive research has shed light on nicotine addiction focused on adolescent demographics, resulting in numerous impactful studies. Furthermore, Dr. Rubinstein is an outspoken advocate for utilizing digital tools to drive behavioral changes, aligning with Achieve Life Sciences’ innovative strategies.
Addressing the Tobacco Epidemic
Achieve Life Sciences is on a mission to combat the nicotine addiction epidemic through the development of cytisinicline. The prevalence of tobacco use continues to be alarming, with millions of adults in the United States smoking combustible cigarettes. The company aims to provide effective treatments to address this pressing public health issue.
Understanding Cytisinicline
Cytisinicline is a natural alkaloid that binds effectively to nicotinic acetylcholine receptors. It’s believed to assist in nicotine cessation by reducing withdrawal severity and the rewarding sensations linked to nicotine use. As an investigational candidate, cytisinicline is in the pipeline for providing a much-needed solution for nicotine addiction treatment.
Investing in Future Health
With no FDA-approved products specifically designed for nicotine e-cigarette cessation readily available, cytisinicline presents a unique opportunity in the market. Ongoing developments in this area are establishing Achieve as a forward-thinking company in nicotine dependence treatment.
Committed to Public Health
Dr. Rubinstein’s new role at Achieve signifies a commitment to enhancing public health through innovative interventions aimed at nicotine cessation. His background in understanding adolescent smoking habits and leading scientific affairs will undoubtedly contribute to the company’s groundbreaking endeavors.
Frequently Asked Questions
What is Achieve Life Sciences?
Achieve Life Sciences, Inc. is a pharmaceutical company focused on developing and commercializing cytisinicline for smoking cessation and nicotine dependence.
Who is Dr. Mark Rubinstein?
Dr. Mark Rubinstein is a medical expert appointed as the Head of Medical Affairs at Achieve Life Sciences, with extensive experience in nicotine dependence research.
What is cytisinicline?
Cytisinicline is a plant-based compound aimed at supporting individuals in quitting nicotine through its interactions with the brain's nicotine receptors.
Why is cytisinicline important?
Cytisinicline is considered a potential breakthrough treatment for nicotine dependence, offering a new option in a market lacking FDA-approved solutions.
How does Dr. Rubinstein's experience benefit Achieve?
Dr. Rubinstein's extensive background in medical affairs and nicotine addiction research is expected to help guide Achieve's initiatives effectively and improve public health outcomes.
